SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-21-031672
Filing Date
2021-06-04
Accepted
2021-06-04 07:05:40
Documents
5
Period of Report
2021-07-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A ljpc-def14a_20210721.htm DEF 14A 1120780
2 GRAPHIC g1qwk351rw5w000003.jpg GRAPHIC 65584
3 GRAPHIC g1qwk351rw5w000004.jpg GRAPHIC 79872
4 GRAPHIC g1qwk351rw5w000001.jpg GRAPHIC 146623
5 GRAPHIC g1qwk351rw5w000002.jpg GRAPHIC 146623
  Complete submission text file 0001564590-21-031672.txt   1726627
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36282 | Film No.: 21994845
SIC: 2836 Biological Products, (No Diagnostic Substances)